You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石药业(02616.HK)在2019年ASCO大会公布CS1001-101临床试验数据
阿思达克 06-03 07:52

基石药业(02616.HK)公布,在2019年美国临床肿瘤学会(ASCO)年会上,以海报形式公布CS1001-101的临床试验更新数据。

CS1001-101是一项针对晚期实体瘤或淋巴瘤患者展开的1a/1b期、开放性、多剂量给药的剂量探索和扩展研究。试验数据显示,CS1001耐受性良好,具有预期的药代动力学特徵,在各种类型的肿瘤中都能观察到持久的抗肿瘤活性。数据显示CS1001对多种实体瘤和淋巴瘤有效。

公司董事长、执行董事兼首席执行官江宁军博士表示,CS1001也是基石药业三款肿瘤免疫骨干(backbone)产品之一。公司已为这一候选药物制定系统的临床开发计划,用於评估它单药及联合疗法在治疗肺癌、胃癌和其他晚期肿瘤上的潜力。

公司首席医学官杨建新博士表示,非常高兴地公布CS1001的最新数据来进一步验证它的安全性和有效性。这些数据也将支持CS1001在注册性试验中的持续开发。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account